Lung Cancer
News from the FDA/CDC
FDA Approves Neoadjuvant/Adjuvant Durvalumab for NSCLC
The drug was approved alongside platinum-containing chemotherapy in the neoadjuvant setting and as monotherapy in the adjuvant setting.
From the Journals
Immunotherapy and Survival in Advanced NSCLC: Does Obesity Matter?
Researchers evaluated 31,257 patients with advanced NSCLC from Japan who received immune checkpoint inhibitors or conventional chemotherapy.
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.
From the Journals
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
Researchers evaluated whether greater reductions in grade 3 chemotherapy-related toxicities occurred with geriatric assessment-driven...
News from the FDA/CDC
FDA Approves First Engineered Cell Therapy for a Solid Tumor
This T-cell receptor therapy modifies existing receptors to recognize an array of antigens on the surface of cancer cells.
From the Journals
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
Researchers analyze data from more than 17,000 patients who died of cancer between 2012 and 2017.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Pulmonary Perspectives®
Changing the tumor board conversation: Immunotherapy in resectable NSCLC
Immunotherapy has transformed the treatment landscape of NSCLC and enhanced survival rates.
Feature
FDA Calls AstraZeneca’s NSCLC Trial Design Into Question
ODAC: A trial’s design makes it impossible to tell whether patients with resectable NSCLC tumors benefited from durvalumab before surgery, after...
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.